Doximity, Inc. (NYSE:DOCS – Get Free Report) saw some unusual options trading activity on Thursday. Investors bought 6,661 put options on the stock. This is an increase of 140% compared to the average volume of 2,778 put options.
Key Doximity News
Here are the key news stories impacting Doximity this week:
- Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
- Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
- Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
- Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
- Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?
- Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares
Insider Buying and Selling
In related news, Director Kira Scherer Wampler sold 9,000 shares of Doximity stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $26.06, for a total value of $234,540.00. Following the completion of the sale, the director directly owned 19,839 shares in the company, valued at approximately $517,004.34. This trade represents a 31.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,309 shares of Doximity stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $25.77, for a total transaction of $59,502.93. Following the completion of the sale, the insider owned 89,396 shares of the company’s stock, valued at $2,303,734.92. This represents a 2.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 18,055 shares of company stock worth $456,061. Corporate insiders own 31.30% of the company’s stock.
Hedge Funds Weigh In On Doximity
Doximity Price Performance
NYSE DOCS traded up $0.92 during trading hours on Friday, hitting $18.93. 12,352,144 shares of the company’s stock traded hands, compared to its average volume of 4,601,587. Doximity has a 52 week low of $17.15 and a 52 week high of $76.51. The firm has a market capitalization of $3.50 billion, a price-to-earnings ratio of 19.12, a P/E/G ratio of 1.28 and a beta of 1.36. The stock has a fifty day simple moving average of $23.94.
Doximity declared that its Board of Directors has authorized a stock buyback program on Thursday, February 5th that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 8% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its stock is undervalued.
Analyst Ratings Changes
DOCS has been the topic of several research reports. Mizuho dropped their target price on shares of Doximity from $34.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday. Loop Capital set a $31.00 target price on shares of Doximity in a research note on Tuesday, March 17th. Morgan Stanley dropped their price target on Doximity from $49.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday. Truist Financial reaffirmed a “hold” rating and issued a $19.00 price objective (down from $29.00) on shares of Doximity in a report on Thursday. Finally, KeyCorp cut Doximity from an “overweight” rating to a “sector weight” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and fourteen have assigned a Hold rating to the company. According to data from MarketBeat.com, Doximity has an average rating of “Hold” and a consensus target price of $30.62.
Read Our Latest Analysis on Doximity
Doximity Company Profile
Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.
The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.
Read More
- Five stocks we like better than Doximity
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
